ENScientists at Heidelberg Faculty of Medicine at Heidelberg University and the Berlin Institute of Health at Charité (BIH) have uncovered a vital biological mechanism that explains why low doses of genetically engineered immune cells successfully eliminate tumor cells in some cancer patients while remaining ineffective in others. By analyzing clinical data and therapeutic cell products, the research team identified a distinct subgroup of chimeric antigen receptor T cells, or CAR T cells, that determines treatment success even when total cell numbers are low. Published in Nature Communications, these findings provide a foundation for developing predictive biomarkers, improving clinical outcomes, and reducing the financial burden of advanced immunotherapies for patients facing complex hematological cancers.
The Challenge of Advanced Blood Cancers and Current Immunotherapies
Hematological malignancies, which include various forms of leukemia, lymphoma, and multiple myeloma, represent a complex group of cancers that originate in the blood-forming tissues and lymphatic system. While many patients achieve long-term remission through conventional treatments such as systemic chemotherapy, targeted molecular agents, or radiotherapy, a significant proportion of individuals experience disease relapse or develop resistance to standard therapeutic options. For these patients with relapsed or refractory blood cancers, cellular immunotherapies have emerged as a groundbreaking medical advancement, offering a potential path forward when conventional protocols no longer yield clinical benefits.
Among the most promising advanced immunotherapies is chimeric antigen receptor T-cell therapy, commonly known as CAR T-cell therapy. This sophisticated procedure involves collecting a patient’s own immune cells, specifically T lymphocytes, through a specialized blood filtration process called leukapheresis. In specialized laboratory facilities, these immune cells are genetically modified to express synthetic receptors on their surface, enabling them to recognize specific molecular structures on malignant target cells. Once re-infused into the patient’s bloodstream, these engineered immune cells seek out and destroy cancer cells with remarkable precision, often maintaining long-term vigilance against disease recurrence.
Despite its impressive clinical efficacy, CAR T-cell manufacturing remains an extraordinarily complex, labor-intensive, and time-consuming process. Preparing therapeutic cell doses requires expanding the engineered cells in controlled laboratory environments over several weeks. In clinical practice, producing the ideal quantity of high-quality cells is not always achievable due to patient-specific biological factors. Patients facing low cellular yield often receive products with uncertain treatment prospects alongside potential risks of severe side effects, or their manufactured treatments are discarded entirely, delaying crucial medical care.
Uncovering the Functional Cell Subgroup Behind Therapy Success
To address the biological uncertainties surrounding variable treatment outcomes, a collaborative research consortium analyzed therapeutic cell samples and clinical data from the HD-CAR-1 trial. The multi-center investigation involved key medical and scientific institutions in Germany, including the Heidelberg Faculty of Medicine, the German Cancer Research Center (DKFZ), the National Center for Tumor Diseases (NCT), and the Berlin Institute of Health at Charité (BIH). Using state-of-the-art single-cell sequencing and high-resolution functional profiling, the team conducted detailed evaluations of CAR T-cell products administered across various dosage levels to patients with advanced blood cancers.
The research team discovered that treatment efficacy relies heavily on a specific, previously uncharacterized subgroup of CAR T cells rather than the total volume of infused cells. These highly potent immune cells possess a distinct molecular profile that confers exceptional tumor-killing capacity while lacking two specific surface markers that allow researchers to isolate and quantify them. The findings demonstrate that when this specific cell population is abundant within a manufactured therapy, patients can achieve complete biological responses even if the overall administered dose of CAR T cells is relatively low.
According to Prof. Dr. med. Michael Schmitt, Professor of Cellular Immunotherapy at the Heidelberg Faculty of Medicine and Head of the Cell and Immunotherapy Research Program within the Department of Hematology, Oncology and Rheumatology at Heidelberg University Hospital, this discovery shifts the therapeutic focus from quantity to quality. As one of the senior authors of the study published in Nature Communications, Prof. Schmitt emphasized that measuring the precise concentration of these highly functional cells could serve as a reliable biomarker for predicting clinical success in low-dose therapeutic settings.
Pre-Existing Immune Health and Biomarker Applications
Crucially, the collaborative study revealed that the therapeutic potency of a final CAR T-cell product is established well before the manufacturing process begins in the laboratory. Co-senior author Prof. Dr. Simon Haas, who conducts research at the Center of Genomic Medicine at BIH at Charité, the Max Delbrück Center for Molecular Medicine in Berlin, and Queen Mary University of London, noted that the baseline state of a patient’s immune system plays a decisive role in cell preparation. Patients whose initial blood samples contained robust, functional immune cells yielded significantly more effective cellular products than those with compromised immune profiles.
The investigation highlighted that elevated levels of immune-suppressive cells in a patient’s original blood sample hinder the development of highly potent CAR T cells during laboratory expansion. First author Schayan Yousefian, a doctoral researcher in Prof. Haas’s laboratory, explained that molecular indicators predicting the ultimate quality and success of a CAR T-cell product can be detected directly in patient blood samples prior to cellular collection and genetic engineering. Identifying these early biological signatures allows clinicians to assess therapeutic feasibility before undertaking costly and time-intensive cell manufacturing workflows.
The identification of this functional cell subgroup and its baseline blood indicators opens major possibilities for refining patient selection criteria and therapeutic protocols. By screening blood samples prior to leukapheresis, medical teams can determine whether a patient is likely to produce a highly functional CAR T-cell product or if additional supportive interventions are necessary. This predictive strategy promises to improve clinical decision-making, ensuring that patients receive therapies tailored to their unique biological profile while avoiding unnecessary treatment delays.
What the Findings Mean for Patients Seeking Treatment in Germany
For international patients considering advanced cancer therapy in Germany, these scientific findings represent an important step toward more precise, individualized care. University hospitals and specialized comprehensive cancer centers across Germany are at the forefront of translating such translational research into daily clinical practice. By moving away from rigid dosage thresholds and focusing on functional cell quality, German centers aim to maximize treatment success for patients who might previously have been excluded from CAR T-cell protocols due to low cellular yield during manufacturing.
While these findings mark a significant scientific breakthrough, the research team emphasizes that additional clinical studies are required to fully integrate these biomarkers into standard care. Ongoing research projects are focused on establishing exact threshold numbers for the highly functional CAR T-cell subgroup and validating predictive models in larger patient cohorts. Patients planning consultation at German medical centers can discuss with their treating oncologists whether prospective biomarker testing or specialized low-dose protocols are appropriate for their individual diagnosis and disease stage.
Furthermore, these insights carry profound economic and structural implications for global healthcare systems. CAR T-cell therapies currently represent one of the most expensive treatment options in oncology, often costing several hundred thousand euros per therapeutic dose. By optimizing cell manufacturing processes and avoiding the production or administration of low-potency products, healthcare providers can conserve vital medical resources while delivering safer, highly effective personalized immunotherapies to patients in need.
Source: Universitätsklinikum Heidelberg